Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $40.9 million.

  • Integra Lifesciences Holdings' Cash from Operations rose 8192.57% to $40.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.3 million, marking a year-over-year decrease of 3499.77%. This contributed to the annual value of $129.4 million for FY2024, which is 755.46% down from last year.
  • Per Integra Lifesciences Holdings' latest filing, its Cash from Operations stood at $40.9 million for Q3 2025, which was up 8192.57% from $8.9 million recorded in Q2 2025.
  • In the past 5 years, Integra Lifesciences Holdings' Cash from Operations registered a high of $91.3 million during Q2 2021, and its lowest value of -$11.3 million during Q1 2025.
  • Moreover, its 5-year median value for Cash from Operations was $44.3 million (2022), whereas its average is $46.6 million.
  • Per our database at Business Quant, Integra Lifesciences Holdings' Cash from Operations surged by 23189.68% in 2021 and then plummeted by 17144.58% in 2025.
  • Over the past 5 years, Integra Lifesciences Holdings' Cash from Operations (Quarter) stood at $69.3 million in 2021, then grew by 23.18% to $85.3 million in 2022, then plummeted by 31.15% to $58.8 million in 2023, then decreased by 13.63% to $50.7 million in 2024, then fell by 19.38% to $40.9 million in 2025.
  • Its last three reported values are $40.9 million in Q3 2025, $8.9 million for Q2 2025, and -$11.3 million during Q1 2025.